Indication: Prostaxen (Apalutamide INN) 60 mg is indicated for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC) in adult patients at high risk of developing metastatic disease.

Pharmacology: Apalutamide is a non-steroidal antiandrogen that competitively inhibits androgen binding to the androgen receptor (AR). By blocking AR signaling, apalutamide inhibits prostate cancer cell proliferation and induces apoptosis.

Dosage and Administration: The recommended dosage of Prostaxen (Apalutamide INN) is 240 mg (four 60 mg tablets) taken orally once daily with or without food.

Interactions: Apalutamide may interact with medications that are substrates, inducers, or inhibitors of cytochrome P450 (CYP) enzymes. It may also interact with drugs that affect the QT interval. Patients should inform their healthcare providers about all medications being taken to avoid potential interactions.

Side Effects: Common side effects of apalutamide may include fatigue, hypertension, rash, diarrhea, nausea, weight loss, decreased appetite, and fractures. Serious side effects may include falls, seizures, ischemic heart disease, and thromboembolic events.

Precautions and Warnings: Patients taking Prostaxen (Apalutamide INN) should be monitored for signs of hypertension, fractures, falls, and seizures. Liver function tests should be performed regularly, and patients should be monitored for symptoms of ischemic heart disease and thromboembolic events.

Overdose Effects: In case of overdose, supportive measures should be taken. There is limited information available regarding specific overdose effects of apalutamide, and management should be symptomatic and supportive.